Lodosyn Related Published Studies
Well-designed clinical trials related to Lodosyn (Carbidopa)
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. [2007.05.11]
Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. [2007.01]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007]
Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. [2006.11.27]
Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. [2005.03]
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). [2005.03]
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
Well-designed clinical trials possibly related to Lodosyn (Carbidopa)
Levodopa improves procedural motor learning in chronic stroke patients. [2008.09]
Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. [2008.08.21]
Fatigue in levodopa-naive subjects with Parkinson disease. [2008.08.12]
Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. [2008.04.01]
Levodopa improves skilled hand functions in the elderly. [2008.03]
Levodopa increases memory encoding and dopamine release in the striatum in the elderly. [2008.02]
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]
Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. [2007.12.26]
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. [2007.09]
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. [2007.03]
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. [2006.10.25]
A shift of paradigm: from noradrenergic to dopaminergic modulation of learning? [2006.10.25]
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. [2006.02]
Does levodopa slow or hasten the rate of progression of Parkinson's disease? [2005.10]
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. [2005.01.25]
Other research related to Lodosyn (Carbidopa)
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.10.31]
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. [2008.10.07]
Response of motor complications in Cockayne syndrome to carbidopa-levodopa. [2008.08]
Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. [2008.06]
Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. [2008.06]
Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. [2008.03]
Acute overdose with controlled-release levodopa-carbidopa. [2008.03]
Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. [2008.02.28]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007.11]
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. [2007.10]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007.06.14]
Carbidopa/levodopa-responsive myoclonus. [2007.02.15]
Clinical Efficacy of a Single Afternoon Dose of Effervescent Levodopa-Carbidopa Preparation (CHF 1512) in Fluctuating Parkinson Disease. [2007]
Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. [2007]
Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. [2006.12]
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. [2006.10]
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. [2006.10]
The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. [2006.07]
Effective treatment with levodopa and carbidopa for hypomyelination with atrophy of the basal ganglia and cerebellum. [2006.06]
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. [2006.03]
Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. [2006.01]
Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa. [2005.10]
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. [2005.07]
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination.] [2005.05]
Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. [2005.02.16]
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. [2005.02]
A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. [2005.01]
Other possibly related research studies
Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol. [2007.01]
Safety and tolerability of adjunctive Tolcapone therapy in early Parkinson's disease patients. [2006.11.21]
Osmotic demyelination and hypertonic dehydration in a 9-year-old girl: changes in cerebrospinal fluid myelin basic protein. [2006.11]
Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy. [2006.11]
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias. [2006.09]
[Case of juvenile parkinsonism in pregnancy] [2006.06]
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. [2006.10]
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). [2006.09]
Levodopa can worsen tremor associated with dystonia. [2006.10]
Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. [2006.10]
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease. [2006.09]
Recognition and treatment of Alzheimer's disease: a case-based review. [2006.03]
Familial dopa-responsive cervical dystonia. [2006.02.28]
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint. [2006.01]
Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson's Disease. [2005.08]
[Continuous treatment with levodopa of Parkinson disease] [2005.10.06]
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. [2006.03]
Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. [2005.09]
Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease. [2006.01]
6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia. [2005.07]
Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease. [2005.03]
[18F]FDOPA PET and clinical features in parkinsonism due to manganism. [2005.04]
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. [2005.01]
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. [2005.01.30]
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. [2005.03]
Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. [2006.11.14]
The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. [2006]
Gateways to clinical trials. [2006.09]
A comprehensive approach to Parkinson's disease. How to manage fluctuating motor and nonmotor symptoms. [2006.06]
Broadening the phenotype of childhood-onset dopa-responsive dystonia. [2006.08]
Approach to diagnosis of Parkinson disease. [2006.07]
Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum. [2006.08]
Gateways to clinical trials. [2006.05]
Spinal myoclonus following combined spinal-epidural anaesthesia for Caesarean section. [2006.06]
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. [2006.07]
Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash--a case report. [2005.10]
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. [2006.06]
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. [2006.03]
Persistence of hyperprolactinemia after treatment of primary hypothyroidism and withdrawal of long term use of estrogen: are the tuberoinfundibular dopaminergic neurons permanently lesioned? [2005.06]
Parkinson's disease management strategies. [2006.01]
Cocaine craving, euphoria, and self-administration: a preliminary study of the effect of catecholamine precursor depletion. [2005.12]
Gateways to clinical trials. [2005.09]
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study. [2005.09]
Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. [2005.08.01]
The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease. [2005.12]
Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. [2006.03]
The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. [2005.09]
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. [2005.06]
Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. [2005.08]
Review of awakening agents. [2005.02]
|
